Press Releases
Back to Press Releases >
BioRestorative Therapies Signs Research and Development Agreement with Rohto Pharmaceutical
BioRestorative Therapies
BioRestorative Therapies Signs Research and Development Agreement with Rohto Pharmaceutical

JUPITER, Fla. (March 25, 2014) – BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB: BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that it has entered into a Research and Development Agreement (“Agreement”) with Rohto Pharmaceutical Company, Ltd. (“Rohto”). Under the Agreement, BRT has been engaged to provide stem cell research and development services.

Rohto is a Japanese global pharmaceutical company with approximately $1.3 billion in sales that develops new technology for the medical and cosmetics markets.

“BioRestorative Therapies has expertise in cell biology with considerable skills in culturing stem cells, and we are delighted that Rohto has selected BRT to assist it with its cell based therapeutic program,” said Mark Weinreb, Chief Executive Officer of BRT. “We look forward to a productive relationship with this new prestigious partner."

About Rohto Pharmaceutical Company, Ltd.

Founded in 1899, Rohto Pharmaceutical is the second-largest consumer health company in Japan, and is a world leader in the manufacturing and marketing of pharmaceuticals, cosmetics, and skincare and healthcare products. Rohto has global operations and its products are available in more than 150 countries.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. ( develops products and medical procedures using cell and tissue protocols, primarily involving adult stem cells, including:

· brtxDISC™ (Disc Implanted Stem Cells) is an investigationalnon-surgical treatment for protruding, bulging and herniated lumbar discs that is intended for patients who have failed non-invasive procedures and face the prospect of surgery. The treatment involves culturing a patient’s own stem cells and then delivering them via a proprietary medical device to thedamaged region of the disc in an outpatient procedure.
· ThermoStem® is a treatment using brown fat stem cellsthat is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels.
· brtx-C Cosmetic is based on the development of a human cellular extract that has been demonstrated in in vitro skin studies to increase the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.

The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls® brand at

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investor Contacts:

Kim Sutton Golodetz
Bruce Voss

# # #

BioRestorative Therapies: A Stem Cell Biotechnology Company